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biosynthesis and contains vicinal RGD motif that bind speciﬁcally to aVb3
and aVb5 integrins. Since chondrostatin reaches the highest level during
cartilage formation and it inhibits angiogenesis, it is an excellent candidate
for the molecular mechanism by which cartilage remains avascular.
A10 TRANSFORMING GROWTH FACTOR-BETA INDUCES
PERSISTENT SYNOVIAL FIBROSIS WHILE CONNECTIVE
TISSUE GROWTH FACTOR-INDUCED FIBROSIS IS
REVERSIBLE. ROLE FOR LYSYS HYDROXYLASE
E.N. Blaney Davidson1, E.L. Vitters1, N. Oliver2, W.B. van den Berg1,
P.M. van der Kraan1. 1University Medical Centre St. Radboud, Nijmegen,
NETHERLANDS, 2FibroGen Inc., South San Francisco, CA, USA
Purpose: The main characteristics of osteoarthritis are cartilage dam-
age, osteophyte formation and synovial ﬁbrosis. Synovial ﬁbrosis can
contribute to the loss of the function of an OA joint. TGF-b is considered
one of the main players in ﬁbrotic diseases. However, CTGF, which can be
induced by TGF-b, has been reported to be an important player as well,
stated to contribute to maintenance of ﬁbrotic tissue. We investigated the
underlying mechanism in that leads to the observed difference in ﬁbrosis
persistence between TGF-b- and CTGF.
Methods: We injected C57Bl/6 mice intra-articularly with Ad-TGF-b or
Ad-CTGF. After 3, 7 and 21 days knee joint synovial tissue was isolated
for RNA isolation or whole knee joints for histology. With Q-RT-PCR
relative mRNA levels were determined of matrix molecules, proteases,
protease inhibitors, and growth factors. To analyze the enzymes involved
in collagen cross link formation, mRNA expression of lysyl hydroxylase
(LH) was determined.
CTGF-levels induced by TGF-b were measured by ELISA in 24 hour
patella-synovial wash-outs of C57Bl/6 mice intra-articularly injected with
Ad-TGF-b (3, 7 and 14 days).
Results: TGF-b and CTGF induced synovial ﬁbrosis in murine knee joints
as shown by histology (as observed by an increase in synovial width).
However, TGF-b-induced ﬁbrosis was very persistent, whereas CTGF-
induced ﬁbrosis resorbed by day 28.
TGF-b induced elevated collagen type I and very high levels of aggrecan
expression and hardly any changes in collagen type II and III. CTGF
induced no clear changes in collagen type I, II and III. CTGF even
decreased aggrecan expression (day 21 only).
CTGF induced no changes in MMP3, -9, -13, ADAMTS-4 or -5, whereas
TGF-b increased MMP-3, -13 and ADAMTS4. Thus elevated levels of
matrix degrading enzyme expression cannot explain the less persistent
CTGF-induced ﬁbrosis.
TIMP1 (associated with matrix accumulation in ﬁbrotic disorders), was
highly up regulated by TGF-b (all days) and only slightly up regulated by
CTGF (day 7). TGF-b also induced elevated mRNA levels of TGF-b1 and
CTGF.
Only TGF-b induced high levels of LH expression, especially LH2b, which
has been implicated in hard-to-degrade collagen linkage and was found
up regulated in ﬁbrotic lesions.
As TGF-b can induce CTGF and up regulated CTGF mRNA in our
experiments, we measured CTGF levels in 24 hour patella-synovial wash
outs and found that TGF-b induced 64 ng CTGF/ml after 3 days and that
CTGF levels were still elevated by day 14.
Conclusions: TGF-b induced increased collagen type I and aggrecan
mRNA levels in synovial tissue, but also high levels of degrading enzymes.
The latter does not explain the persistent nature of TGF-b versus CTGF-
induced synovial ﬁbrosis. Lack of collagen type I mRNA induced by
CTGF corresponds to ﬁndings of other groups. Despite this fact, ﬁbrosis
is found. Only TGF-b induced high levels of TIMP1 expression, which
was previously found associated with strain dependent ﬁbrosis sensitivity
in mice and implicated in accumulation of ECM in ﬁbrotic disorders.
TGF-b, not CTGF, induced high levels of LH which are crucial for ECM
cross linking. Moreover, LH2b was reported by van der Slot et al. to
induce harder-to-degrade crosslinks compared to LH2a. The 2b splicing
variant was highly expressed upon stimulation with TGF-b. Since TGF-b
clearly up regulated MMP expression a dominant role for TIMP appears
unlikely. The strong induction of LH2b by TGF-b compared to CTGF, and
consequently harder to degrade cross links, appears to be the most likely
cause of the induction of irreversible ﬁbrosis by TGF-b.
A11 EFFICACY OF A SINGLE ULTRASOUND GUIDED INJECTION
IN HIP OSTEOARTHRITIS
I. Atchia1, M. Reed1, D. Kane2, J. Isaacs2, F. Birrell1. 1Northumbria
Healthcare NHS Foundation Trust, Northumberland, UNITED KINGDOM,
2Musculoskeletal Research Group, Newcastle, UNITED KINGDOM
Purpose: There is increasing evidence for intra-articular hyaluronic acid
and especially corticosteroids in the treatment of osteoarthritis (OA) from
studies using ﬂuroscopy guidance or triple ultrasound guided injections.
Having previously demonstrated the accuracy of ultrasound guided in-
jection and how competency can be achieved we aimed to demonstrate
the duration of objective improvement in pain, function and global health
assessment in patients with moderate/severe hip OA with a single intra-
articular injection.
Methods: 77 patients with hip OA were recruited to a prospective, ran-
domised controlled trial and randomised to one of four groups: standard
care (non-injection group), normal saline (3mls), non-animal stabilized
hyaluronic acid (durolane, 3mls/60mg) and methylprednisolone acetate
(depomedrone, 3mls/120mg). All patients met the ACR criteria for hip
OA. Those in the injection groups received a single ultrasound guided
injection. All baseline data were obtained with both patients and inves-
tigators blinded to the group allocation, and injection patients remained
blinded throughout the study. The primary outcome measure was ‘worst
pain’ using a numerical rating scale (NRS 0−10), and other outcome mea-
sures included the aggregate pain and function scales of the WOMAC.
These evaluations were performed at baseline and weeks 1, 4, 8 and 16.
Results: Mean age was 69 (SD 8) years. Mean BMI was 28.5 (SD 5.2)
kg×m−2. The 4 groups were matched with respect to age, BMI, and
scores of the outcome measures (ANOVA). At week 1 and week 4 there
was a signiﬁcant improvement in NRS pain, as well as WOMAC pain
and function for the steroid arm with the differences being statistically
signiﬁcant compared to all the other groups; the effect sizes were striking:
1.5 for NRS pain, 1.9 for WOMAC pain and 1.3 for WOMAC function
at week 1. There were 22 responders as deﬁned by the OMERACT-
OARSI responder criteria in an intention to treat analysis at week 1:
14 in the steroid group (74%), 4 in saline group (21%), 2 in durolane
group (11%) and 2 in non-injection group (10%); Chi-squared test for
comparison between the groups, p< 0.001. At 8 weeks the differences
were still signiﬁcant between the steroid group and the saline group (NRS
pain: t test, p 0.018).
Conclusions: This is the ﬁrst single ultrasound guided injection study in
hip OA comparing a moderately high dose of corticosteroid, hyaluronic
acid, a control injection and standard care. Our data demonstrate the
efﬁcacy of intra-articular corticosteroid, with a statistically signiﬁcant and
clinically important improvement in pain and function sustained for at
least 8 weeks post injection, suggesting this is an important and practical
treatment option for those with moderate/severe hip OA.
A12 DOSE DEPENDENT CHONDROPROTECTIVE EFFECTS OF
ALLOGENIC STRO-3+ MESENCHYMAL PRECURSOR
STEM CELLS FOLLOWING DIRECT INTRA-ARTICULAR
INJECTION INTO JOINTS OF AN OVINE MODEL OF EARLY
OSTEOARTHRITIS
R. Read1, M. Cake1, T. Smith1, C.B. Little2, M.M. Smith3,
R.C. Appleyard3, S. Itescu4, P. Ghosh5. 1Murdoch University, Perth,
AUSTRALIA, 2University of Sydney, Sydney, AUSTRALIA, 3Royal North
Shore Hospital, Sydney, AUSTRALIA, 4Mesoblast Ltd, Melbourne,
AUSTRALIA, 5Mesoblast Ltd, Sydney, AUSTRALIA
Purpose: Purpose: Our previous studies had shown that bilateral total
meniscectomy (BTM) in merino sheep resulted in pathological changes in
articular cartilage (AC), subchondral bone and synovial tissues that were
progressive and simulated the development of early human osteoarthritis
(OA). We previously used this animal model to evaluate potential disease-
modifying OA drugs. Mesenchymal stem cells (MSC) + bio-scaffolds
have been widely investigated for their ability to enhance repair of
chondral/osteochondral defects, but their chondroprotective effects when
injected directly into OA joints has received limited attention. The objective
of this study was to address this deﬁciency using immunoselected Stro-3+
mesenchymal precursor stem cells (MPC) in the BTM model.
Methods: BTM was undertaken in 36 adult Merino wethers. Two weeks
post BTM, joints were randomly injected with either 2mL high MW
Hyaluronan (HA) or 2mL allogenic Stro-3+ MPC suspended in HA. Four
doses of MPC were studied: Group A = 10 million (mil) MPC [n = 6];
Group B = 25 mil MPC [n = 6]; Group C = 100 mil MPC [n = 18] and
Group D = 150 mil MPC [n = 6]. Groups A, B and D were sacriﬁced
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12 weeks post-BTM while Group C were sacriﬁced 12 [n = 6], 24 [n = 6]
and 52 [n = 6] weeks post-BTM. At necropsy, both medial compartments
of BTM joints were scored by 2 blinded observers for AC lesions and
osteophytes (OP) using a 0−4 scale. Synovial tissue and a 5mm wide
coronal osteochondral slice were removed from the mid-line of the femur
and tibia and processed for histochemical and histomorphometric analy-
ses using published methods. Intact patellae were used for topographical
biomechanical AC indentation studies.
Results: Gross morphological scores 12 wks post BTM showed a dose-
dependent effect of MPC on AC integrity and OP formation; 100 mil MPC
emerging as the most effective chondroprotective dose relative to HA
alone. Total AC score ratios (HA+MPC)/(HA) showed 100>150>25=10
while OP ratios were 100>25>10>150 mil MPC. Statistically signiﬁcant
(SS) lower scores were observed for total femoral & tibial AC (p = 0.019)
and total AC and OP (p = 0.009) for Group C MPC joints compared HA
alone. Histomorphometric analysis of Group C MPC+HA tibial plateaus
revealed that AC were thicker than the corresponding HA-AC in the middle
(p = 0.057) and outer regions (p = 0.028); for all regions (p = 0.01). The
mean phase lag for the patellae AC of Group C MPC injected joints
was signiﬁcantly lower than the contralateral patella AC (p = 0.002). Mean
modiﬁed Mankin scores for AC sections from Group C MPC+HA joints
were less than corresponding HA sections but were not SS. There was no
evidence of synovial histopathology modulation. The chondroprotective
effects observed for the 100 mil MPC injected joints diminished with time;
the positive effects noted at 12 and 24 weeks BTM being lost by 52 weeks.
Conclusions: This is the ﬁrst report, as far as we are aware, of a
beneﬁcial therapeutic effect of allogenic Stro-3+ MPC on cartilage in-
tegrity in a model of early OA. MPC/MSC are known to release growth
factors and cytokines and also suppress the production of TNF-alpha
by other cells, while up-regulating anti-inﬂammatory cytokines (eg. Il-4,
Il-10). These paracrine activities of MPC could stimulate chondrocyte
biosynthesis of new matrix but also attenuate local production and activity
of catabolic mediators. The ﬁnding in this study that 100 million MPC were
chondroprotective was consistent with such a mechanism of action.
A13 INTRAARTICULAR LUBRICIN SUPPLEMENTATION IS
CHONDROPROTECTIVE AND PREVENTS CARTILAGE
DEGENERATION IN EXPERIMENTAL OSTEOARTHRITIS
C.R. Flannery1, R. Zollner1, C. Corcoran1, A.R.C. Jones1, A. Root1,
M.A. Rivera-Bermudez1, T. Blanchet1, J.P. Gleghorn2, L.J. Bonassar2,
A.M. Bendele3, E.A. Morris1, S.S. Glasson1. 1Wyeth Research,
Cambridge, MA, USA, 2Cornell University, Ithaca, NY, USA, 3Bolder
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Purpose: Lubricin is a synovial glycoprotein that supplies a friction-
resistant, anti-adhesive coating to the surfaces of articular cartilage,
thereby protecting against arthritis-associated tissue wear and degrada-
tion. We generated and characterized a novel lubricin protein construct,
“LUB:1”, and evaluated its therapeutic efﬁcacy following intraarticular
delivery in a well-characterized rat model of osteoarthritis (OA).
Methods: An optimized lubricin protein construct (designated “LUB:1”),
containing a truncated mucin-like domain, was expressed in stably trans-
fected CHO cells. Puriﬁed LUB:1 was biochemically characterized and
analyzed ex vivo for its ability to bind to and lubricate cartilage surfaces,
and to prevent cellular adhesion. For in vivo studies (IACUC approved),
unilateral OA was induced in the knees of male Lewis rats (n = 20
animals/treatment group) by transection of the medial collateral ligament
and meniscus (‘meniscal tear’-induced OA). At one week post-surgery,
LUB:1 (20mg/40ml), or phosphate-buffered saline (PBS) vehicle (40ml)
was administered by intraarticular injection, with dosing either once per
week or 3 times per week over a subsequent four week period. At the
end of the studies, tissue sections of each knee joint were analyzed
microscopically and assessed for multiple pathological parameters of OA.
Results: LUB:1 maintains functional N-terminal domains which facili-
tate mutimerization, is appropriately substituted with lubricating O-linked
oligosaccharides, and possesses integral C-terminal domains enabling
binding and localization to cartilage surfaces. LUB:1 is an effective carti-
lage boundary lubricant and inhibitor of cellular adhesion. Local delivery
of LUB:1 was therapeutically effective in preventing cartilage degrada-
tion during the progression of OA. Knee joints from rats treated with
LUB:1 developed signiﬁcantly less severe cartilage damage than PBS
(vehicle)-treated animals, and displayed signiﬁcantly reduced cartilage
degeneration scores (general pathology), total joint scores and cartilage
lesion and degeneration width measurements. Strikingly, the width of
severe cartilage lesions, reﬂecting areas of tibial cartilage damage in
which tissue matrix loss extends through 50% or more of the cartilage
depth, was decreased by 83% in response to LUB:1 administered 3 times
per week. Inhibition of loss of viable matrix further indicated beneﬁcial
effects of LUB:1 on overall cartilage tissue preservation (chondrocytes,
proteoglycan and collagen). Subchondral bone scores did not differ be-
tween treatment groups, indicating that joint loading was comparable in all
animals. Evidence of ﬁbroplasia was not observed in response to LUB:1
treatment, thus supporting a favorable tolerability proﬁle for recombinant
lubricin in the treatment of joint diseases.
Conclusions: Intraarticular supplementation of rat knee joints with LUB:1
resulted in signiﬁcant disease-modifying, chondroprotective effects during
the progression of osteoarthritis, by markedly reducing cartilage degener-
ation and structural damage. The use of recombinant lubricin molecules
is thus indicated for novel biotherapeutic approaches in the treatment of
cartilage pathologies associated with osteoarthritis.
A14 CHEMOTAXIS OF HUMAN ARTICULAR CHONDROCYTES
AND MESENCHYMAL STEM CELLS
Y. Mishima, M. Lotz. The Scripps Research Institute, La Jolla, CA, USA
Purpose: Orchestrated movement of cells in a particular direction to a
speciﬁc location is a central process for tissue development, maintenance
and repair. The understanding of cell migration and chemotactic mech-
anisms may lead to the novel therapeutic strategies for tissue repair or
regeneration. The aim of this study was to identify cytokines and growth
factors that are able to induce migration of human articular chondrocytes
and mesenchymal stem cells (MSCs).
Methods: Isolated normal human articular chondrocytes and human
bone marrow-derived MSCs were used. Chemotaxis assays were per-
formed in modiﬁed Boyden chambers using 48-well microchemotaxis
chamber plates with polycarbonate PVP free membranes with 8-mm
pores.
Growth factors were diluted to appropriate concentrations in DMEM/F12
supplemented with 0.1% FBS, and placed in the lower chamber. Approx-
imately 2×104 cells were allowed to attach to the top wells of the insert.
After 24 h incubation, the migrated cells on the lower side of the inserts
were ﬁxed, stained and counted for 4 random ﬁelds per well under light
microscope at 100× magniﬁcation. The results are expressed as total
number of migrated cells.
Results: Progressive chemotactic effects were observed with increasing
FBS concentrations between 0−20%. Among a series of growth factors
and cytokines tested only PDGF induced a signiﬁcant increase in cell
migration. TGFb, VEGF, IGF-1, Il-8, bFGF, BMP-2, BMP-4 and BMP-7
had no signiﬁcant effects on chondrocytes. The PDGF isoforms AB and
BB were more potent than AA. In human articular chondrocytes there
was a signiﬁcant aging related decline in the ability of cells to migrate
in response to serum and PDGF. MSCs signiﬁcantly responded to FBS
and several factors, including FBS, PDGF, VEGF, IGF-1, Il-8, BMP-4 and
BMP-7.
Conclusions: This study demonstrated that directed cell migration is in-
ducible in human articular chondrocytes and MSC and identiﬁed PDGF as
the most potent chemotactic factor. The present results also demonstrate
an aging-related reduction in the migratory response of human articular
chondrocytes. The ability of human articular chondrocytes to migrate in
response to serum and PDGF, supports the potential of augmenting this
cellular response in cartilage repair and tissue engineering.
A15 SUCCESSFUL INTEGRATIVE CARTILAGE REPAIR IN VITRO
CAN BE ACHIEVED BY INHIBITING CHONDROCYTE DEATH
AT THE WOUND EDGE
S.J. Gilbert, S.K. Singhrao, I.K. Khan, V.C. Duance, C. Archer. Cardiff
University, Cardiff, UNITED KINGDOM
Purpose: Experimental wounding of articular cartilage results in necrotic
and apoptotic chondrocyte death at the lesion edge. Viable cells at the
wound edge are critical for producing a repair tissue capable of integrating
with the native cartilage. The aims of this study were to investigate
whether inhibiting the cell death at the wound edge results in enhanced
integrative cartilage repair.
Methods: Full depth, bovine articular cartilage discs (6mm) were har-
vested from the metacarpophalangeal joint of 7-day old calves. Carti-
lage discs were pre-incubated in media containing inhibitors of necrosis
(Necrostatin-1; 30mM) or apoptosis (Z-VAD-FMK, 20mM) prior to cutting
a central 3mm inner core. This core was left in situ to create disc/ring
composites in order to study cartilage-cartilage integration. Cartilage was
cultured for 2-weeks with the above inhibitors and analysed for necrotic
